Ferzoco Stephen J
Dedham Medical Associates, Dedham, Massachusetts, USA.
Int Surg. 2013 Oct-Dec;98(4):399-408. doi: 10.9738/INTSURG-D-12-00002.1.
Repair of contaminated/infected ventral incisional hernias is marked by high rates of recurrence, complications, and/or explantation of synthetic mesh. Biologic mesh products are recommended for repair to permit reconstruction and reduce complications. A systematic review of PubMed, EMBASE, and Cochrane databases identified English-language articles reporting postoperative outcomes (e.g., hernia recurrence, infection, mesh explantation) in patients undergoing contaminated/infected ventral incisional herniorrhaphy. Eleven studies met inclusion criteria and contained quantitative outcome data. All were retrospective chart reviews of biologic mesh use (mostly human acellular dermal matrix). Hernia recurrence and wound infection rates were highly variable and inconsistently reported across studies. Mesh explantation was rarely reported. Outcome variability is likely owing to heterogenous patient populations, surgical technique variations, and follow-up duration. Biologic mesh use in contaminated/infected herniorrhaphy was marked by low reported rates of secondary surgeries for infected mesh removal. Data from large, well-controlled, prospective trials with biologic mesh products are needed.
污染/感染性腹直肌切口疝的修复手术存在较高的复发率、并发症发生率和/或合成补片取出率。推荐使用生物补片进行修复,以实现重建并减少并发症。对PubMed、EMBASE和Cochrane数据库进行的系统综述,确定了报告污染/感染性腹直肌切口疝修补术患者术后结局(如疝复发、感染、补片取出)的英文文章。11项研究符合纳入标准并包含定量结局数据。所有研究均为对生物补片使用情况(主要是脱细胞人真皮基质)的回顾性病历审查。各研究中疝复发率和伤口感染率差异很大,报告也不一致。补片取出情况很少被报告。结局的变异性可能归因于患者群体的异质性、手术技术差异和随访时间。在污染/感染性疝修补术中使用生物补片的特点是,因感染而取出补片的二次手术报告率较低。需要来自使用生物补片产品的大型、严格对照的前瞻性试验的数据。